Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $467.8 million.

  • Kymera Therapeutics' Non-Current Assets rose 23.09% to $573.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $573.7 million, marking a year-over-year increase of 23.09%. This contributed to the annual value of $467.8 million for FY2024, which is 174.44% up from last year.
  • Kymera Therapeutics' Non-Current Assets amounted to $467.8 million in FY2024, which was up 174.44% from $170.4 million recorded in FY2023.
  • Kymera Therapeutics' Non-Current Assets' 5-year high stood at $467.8 million during FY2024, with a 5-year trough of $154.6 million in FY2021.
  • Over the past 3 years, Kymera Therapeutics' median Non-Current Assets value was $183.7 million (recorded in 2022), while the average stood at $274.0 million.
  • Per our database at Business Quant, Kymera Therapeutics' Non-Current Assets skyrocketed by 674.77% in 2020 and then decreased by 16.34% in 2021.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Non-Current Assets stood at $184.8 million in 2020, then dropped by 16.34% to $154.6 million in 2021, then grew by 18.81% to $183.7 million in 2022, then dropped by 7.23% to $170.4 million in 2023, then soared by 174.44% to $467.8 million in 2024.